A randomized, subject-blind, investigator-blind, placebo-controlled, single-dose, dose escalating study evaluating the safety, pharmacokinetics, and pharmacodynamics of UCB4940 in patients with mild to moderate psoriasis

Trial Profile

A randomized, subject-blind, investigator-blind, placebo-controlled, single-dose, dose escalating study evaluating the safety, pharmacokinetics, and pharmacodynamics of UCB4940 in patients with mild to moderate psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors UCB
  • Most Recent Events

    • 13 Nov 2016 Results published in the British Journal of Clinical Pharmacology
    • 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 02 Mar 2013 Primary endpoint amended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top